Clinical Trial Update: A Phase 3 Clinical Trial to Compare RBS-001 to Eylea® in Subjects With Neovascular Age-Related Macular Degeneration [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is planned to compare RBS-001 to Eylea for neovascular age-related macular degeneration. The study is currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• EYLEA (Aflibercept)
• RBS-001

Snippet

Sponsor: Rophibio, Inc. | Conditions: Neovascular Age-related Macular Degeneration (nAMD) | Phase 3 | Status: NOT_YET_RECRUITING